Skip to content

Cancer Parenting Program for the Enhancement of the Quality of Life of Patients With Advanced Cancer and Their Children

Enhancing Connections-Palliative Care: A Cancer Parenting Program for Patients With Advanced Cancer and Their Children

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05477784
Acronym
EC-PC
Enrollment
174
Registered
2022-07-28
Start date
2022-07-19
Completion date
2025-08-15
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Parent-Child Relations, Parenting, Survivorship

Brief summary

This trial examines the usefulness of two educational programs for parents with late-stage cancer who have a 5 - 17 year old child. The programs are designed to enhance the quality of the parent-child relationship and add to the parent's confidence in managing the impact of their cancer on their child. Educational programs may reduce anxiety and depression and improve the well-being and quality of life of parents with advanced cancers and their children. Recruitment occurs nationally via referral to the Fred Hutch/University of Washington Cancer Consortium team.

Detailed description

OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I (ENHANCING CONNECTIONS-PALLIATIVE CARE \[EC-PC\] PROGRAM): Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child. GROUP II (CONTROL): Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.

Interventions

OTHEREducational Intervention

Receive EC-PC program

OTHERInformational Intervention

Receive education booklet

OTHERQuestionnaire Administration

Ancillary studies

Sponsors

University of Washington
Lead SponsorOTHER
National Institute of Nursing Research (NINR)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Only biostatistician will be unmasked.

Intervention model description

2-group randomized control trial: experimental and alternative treatment control group

Eligibility

Sex/Gender
ALL
Age
23 Years to 68 Years
Healthy volunteers
No

Inclusion criteria

* Parents with any type of late-stage, non-curable cancer (determined by TNM stage IV cancer for solid tumors or 2 or more cycles of treatment failure with disease relapse in non-solid tumors) * All therapies are allowable * 23 years (yr.) to 68 yr. Age restriction exists for the patient based on parent having a child ages 5-17 * Patient must have a child (5yr. -17 yr.) living in the home at least 50% of the time and residential with non-ill parent or parent surrogate * Read and write English as one of their languages of choice * Have access to a telephone * Ability to understand and the willingness to sign a written informed consent document. Read and write English as one of their languages of choice

Exclusion criteria

* Patient is in hospice at time of enrollment * Non-ill co-parent does not consent to join study

Design outcomes

Primary

MeasureTime frameDescription
Treatment efficacy assessed by parents' mood (CES-D)At 3 months post-baselineDepressed mood will be measured by the 20-item Center for Epidemiological Studies- Depression Scale (CES-D) (Benazon \& Coyne, 2000; Lewis, Fletcher, Cochrane, \& Fann, 2008; Radloff, 1977). The CES-D Scale measures the recent occurrence of symptoms of depression. For each symptom, the respondent indicates the frequency with which that symptom has occurred during the past week, from "rarely or none of the time (less than 1 day)" to "most or all of the time (5-7 days)." This measure has been well- accepted in both ill and non-ill samples. Internal consistency in three samples from the general population has been reported by Radloff (Radloff, 1977) and ranged between .84 to .85. Validity has been well- established, including its link to the broader concept of "distress" in cancer-related research (Benazon \& Coyne, 2000; Coyne et al., 1987; Given et al., 2004) The internal consistency reliability is 0.85 or higher (Benazon \& Coyne, 2000; Coyne et al., 1987; Given et al., 2004).
Treatment efficacy assessed by parents' anxiety [Spielberger State-Trait Anxiety (STAI, state scale)]At 3 months post-baselineState anxiety will be measured by the state component of the State-Trait Anxiety Inventory. This 20-item self-report questionnaire evaluates current feelings of apprehension, tension, nervousness, and worry. The respondent circles a response that best depicts their current feelings best. Response options range from \[1 - Not at all\] to \[5 - Very much so\]. Sample items include "I feel calm", I am tense." Higher scores denote greater anxiety. Internal consistency reliability is 0.90 or above in community and population samples \[Edwards and Clarke, 2004\]
Parent's confidence in being able to talk with her child about the child's cancer-related concerns (CASE Help Child Subscale)At 3 months post-baselineParenting Self-efficacy: Measured by the Help Child subscale of the parent-reported cancer Self-efficacy Scale (CASE). The Help Child subscale (9 items) measures the parent's confidence in being able to talk with her child about the child's cancer-related concerns; e.g., "I can assist my child to talk out his/her worries about my cancer." Structured response options range from "Not at all confident" (1) to "Very confident." The internal consistency reliability The internal consistency reliabilities in the EC seminal trial with parents with early stage cancer was 0.97.
Parents' skills in helping their child cope and manage the toll of the parents' cancer (Connecting and Coping Subscale)At 3 months post-baselineParenting skills will be measured by the parent reported Parenting Skills Checklist: Connecting and Coping subscale developed by the study team and tested for reliability and validity in a 6-state randomized control trial (Lewis et al., 2015). The measure describes the observable interactional behaviors parents can use to assist their child disclose, discuss, and cope with the parent's cancer. The developmental-contextual model of parenting was the conceptual basis for the measure. An example item on the Connecting and Coping subscale includes, "I work with my child to help my child manage the child's stress related to my cancer."
Child-Behavioral Emotional Functioning: Anxious/Depressed, Internalizing, Externalizing scores on CBCLAt 3 months post-baselineThe child's behavioral-emotional adjustment will be measured by the Anxious/Depressed, Internalizing and Externalizing scores of the CBCL which is part of the Child Behavior Checklist. This measure will be obtained from both the ill parent and the non-ill parent/parent surrogate. Response options range from 0 to 2 from "Not True (as far as you know)" to "Somewhat or Sometimes True" to "Very True or Often True." This score is part of the Internalizing score of the CBCL that measures the child's fearful, inhibited, and over-controlled behavior. The internal consistency reliabilities for the EC clinical trial were 0.90 for the Internalizing score and 0.94 for the Externalizing score. For the current study, we will use the CBCL form for 6-18 year-olds and its computer software.

Secondary

MeasureTime frameDescription
Effects of parents' symptom burden on treatment outcomes: Condensed Memorial Symptom Assessment scale (CMSAS) - Physiological symptoms subscaleAt 3-months post-baselineUsing Linear Mixed Models, will examine the moderator effects of the diagnosed parent's symptom burden on intervention outcomes. Will be assessed using the physiological symptoms subscale (range of scores 0-4).

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORFrances M Lewis, RN, MN, PhD

University of Washington

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026